

CURRICULUM VITAE
SUSAN L. SCARBERRY, MD
May 31, 2015

PERSONAL DATA:

Business Address: Sanford Neuroscience Clinic
700 1st Avenue South
Fargo, ND 58103
(701) 234-4036
(800) 437-4010

FIELD OF INTEREST:

Adult Neurology
Clinical Electromyography and Neuromuscular Disease
Multiple Sclerosis: Medical Director of the Sanford Health Multiple Sclerosis Center
ALS

BOARD CERTIFICATION:

American Board of Psychiatry and Neurology, June 1995, Certificate No. 41599.
Recertification 2005-2015
American Board of Electrodiagnostic Medicine, April 12, 1997 Certificate No. 2313
Recertification 2008-2017
American Board of Psychiatry and Neurology, Diplomate in neuromuscular medicine,
August 2011, Certificate No. 142480
The Consortium of Multiple Sclerosis Centers, Multiple Sclerosis Certified Specialist,
February 2009

EDUCATION:

Electromyography and Neuromuscular Fellowship
Case Western Reserve University
University Hospitals of Cleveland, Cleveland Ohio
July 1993 - June 1994

Neurology Residency
Case Western Reserve University
University Hospitals of Cleveland, Cleveland, Ohio
July 1990 - June 1993
Chief Resident - July 1992 - June 1993

Internal Medicine Internship

Medical College of Ohio, Toledo, Ohio
July 1989 - June 1990

Doctor of Medicine
Medical College of Ohio, Toledo, Ohio
July 1985 - June 1989

Medical Technologist
Fairview General Hospital, Cleveland, Ohio
June 1984

Bachelor of Arts
Miami University, Oxford, Ohio
May 1983

MEMBERSHIP/OFFICES:

Medical Director, Sanford Health Multiple Sclerosis Center 2001 to present
Medical Director, Sanford Health ALS Clinic, 2009-2011
Clinical Associate Professor, Division of Neurology, Department of Neuroscience
University of North Dakota, School of Medicine and Health Sciences
North Dakota Medical Association 2001- present
Dakota Chapter Board Member, National Multiple Sclerosis Society, 2001-2006
Mid Central States Chapter, Clinical Advisory Committee, National Multiple Sclerosis
Society, 2006 - present
Member of the Consortium of Multiple Sclerosis Centers
Fellow, American Association of Neuromuscular and Electrodiagnostic Medicine
Active, American Academy of Neurology
Louisiana State Medical Association 1994 - 2001
East Baton Rouge Parish Medical Society
Medico Legal Committee, 1999 – 2001

RESEARCH EXPERIENCE:

1988 Research Technician/Student Independent Study Clerkship
Henry Ford Hospital, Detroit, MI
“Enhancement of Brain Lesions in MRI Imaging of Stroke Patients”
Advisor: Joe Windham, Ph.D.

1998 MSTRAC: A Registry of Multiple Sclerosis Treatment and Care

2002 “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter

Study to Determine the Safety and Efficacy of Natalizumab in Subjects with Relapsing-Remitting MS”, Principle Investigator for MeritCare Multiple Sclerosis Center. Principal Site Investigator and Treating Neurologist.

2002 “A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Safety Study of Natalizumab in Combination with Glatiramer Acetate in Subjects with Relapsing-Remitting Multiple Sclerosis” Principal Site Investigator and Treating Neurologist.

2002 “An Open-label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Natalizumab in Subjects with Multiple Sclerosis Who Have Completed Studies C-1801, C-1802, or C-1803” Principal Site Investigator and Treating Neurologist.

2004 “A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients with Relapsing Remitting Multiple Sclerosis” Principal Site Investigator and Treating Neurologist.

2005 “Genetech Hermes U2787G Protocol: A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study To Evaluate The Safety and Efficacy Of Rituximab In Adults With Relapsing-Remitting Multiple Sclerosis. Principal Site Investigator and Treating Neurologist.

2006 “Preventing Neutralizing Antibody Formation in Multiple Sclerosis Patients Treated with Subcutaneous Interferon Beta-1a (Rebif)” Principal Site Investigator

2006 “GA9016/FORTE: A Multinational, Multicenter, Randomized, Parallel-Group, double-Blind Study to Compare the Efficacy, Tolerability, and Safety of Glatiramer Acetate injection 40 mg/ml to that of Glatiramer Acetate injection 20 mg/ml Administered Once Daily by Subcutaneous Injection in Subjects with Relapsing Remitting (R-R) Multiple Sclerosis (MS)”. Principal Site Investigator

2006 “A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy Of C105 in Persons with Multiple Sclerosis with Cognitive Impairment”. Principal Site Investigator

2007 “Tysabri Global Observational Program in Safety”, Protocol TYGRIS 101MS402. Principal Site Investigator

2007 “A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study, to Evaluate the Safety, Tolerability and Efficacy of Daily Oral Administration of Laquinimod 0.6 mg in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS)”, Protocol No: MS-LAQ-301. Principal Site Investigator

2008 “A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Oral Clabribine in Subjects with a First Clinical Event at High Risk of Converting to MS”, Protocol No: 28821. Principal Site Investigator

2008 “A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of Nerispiridine 50 mg, 100 mg and 200 mg in Patients with Multiple Sclerosis”, Protocol No: DRI10566. Principal Site Investigator

2009 “Clinical Characteristics of Late-onset Demyelinating Disease”
Emiru, Tenbit M.D. PhD, Carpenter, Adam M.D, Scarberry, Susan M.D,
Luzzio, Chris M.D, Freeman, Jerome M.D, Parry, Gareth M.D

2009 “A Multinational, Multicenter, Open-label, Single-assignment Extension of the MS-LAQ-301 (ALLEGRO) Study , to Evaluate the Long-term Safety, Tolerability, and Effect on Disease Course of Daily Oral Laquinimod 0.6 mg in Subjects with Relapsing Multiple Sclerosis", Protocol No: MS-LAQ-301E. Principal Site Investigator.

2010 “JCV Antibody Program in Patients with Relapsing Multiple Sclerosis - STRATIFY 2”, Biogen Idec Protocol No: 101JC402. Principal Site Investigator

2013 "TRANSITION: A 2 year Observational Study to Evaluate the Safety Profile of Fingolimod in Patients with Multiple Sclerosis who Switch from Natalizumab to Fingolimod”, Protocol No: CFTY720D2405. Principal Site Investigator

2013 “A Multicenter, Open-Label, Single-Arm Study of Gastrointestinal Tolerability in Relapsing-Remitting Multiple Sclerosis Patients Receiving Oral BG00012 (dimethyl fumarate)", Protocol No: MANAGE 109MS403 Optuminsight RRMS. Principal Site Investigator

2014 “Treatment of Progressive Forms of Multiple Sclerosis with Pulsed ACTH (Acthar Gel)”, Protocol No: ACTH-20712. Principal Site Investigator

PUBLICATIONS:

Roohani P, Emiru T, Carpenter A, Luzzio C, Freeman J, Scarberry S, Beaver G, Davidson L, Parry G: Late onset multiple sclerosis: Is it really late onset? Multiple Sclerosis and Related Disorders 2014; in press, <http://dx.doi.org/10.1016/j.msard.2014.02.004>

Katirji B, Wilbourne A, Scarberry S, Preston D: Intrapartum Maternal Lumbosacral Plexopathy. Muscle and Nerve 2002;26:340-347.

Scarberry S, Katirji B: Electrophysiologic Findings in Intrapartum Lumbosacral Plexopathy. Neurology 1994;44 (suppl 2) :159.Abstract.

Katirji B, Scarberry S, and Westbrook EL.: Precipitous Segmental Denervation in Cervical Syring. Muscle and Nerve, 1994;17:9:1108-09.

Contributing author of: Learner A, The Little Black Book of Neurology. Third ed. St. Louis, Mosby Year Book, 1994.

STAFF APPOINTMENTS:

Sanford Health System	2010- present
Clinical Associate Professor University of North Dakota	2002- present
Meritcare Health System	2001- 2010
Our Lady of the Lake Regional Medical Center	1994- 2001
Baton Rouge General Medical Center - Bluebonnet	1994-2001
Baton Rouge General Medical Center - Mid-City	1994- 2001